Another limitation of the intranasal insulin literature is a relative lack of data from middle-aged individuals (for example, those aged 50 to 60) who may be at the earliest stages of measurable cognitive decline [29, 30] and AD-related neurobiological processes [31]. This evidence concerns the gene INS and Alzheimer disease.